Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea.

Sunggyun ParkSoon-Hee ChangJae Hee LeeJong Ho LeeJi Yeon HamYu Kyung KimSang-Gyung KimNam Hee Ryoo

Published in: PloS one (2022)

Anti-SARS-CoV-2 antibody persisted for at least 13 weeks at a high COI in patients with COVID-19. A decreasing COI pattern up to fifth week may be associated with a poor prognosis of COVID-19. As new treatments and vaccines are introduced, it is important to monitor continuously the usefulness of anti-SARS-CoV-2 antibody assays.

Keyphrases

sars cov
poor prognosis
coronavirus disease
respiratory syndrome coronavirus
long non coding rna
high throughput
randomized controlled trial
clinical trial
study protocol